OptiDose Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

OptiDose Technology

Catalent’s OSDrC® OptiDose™ enables design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing processes.  This expands tableting capabilities in many areas that differentiate beyond existing technologies.

OptiDose technology provides the flexibility to design single or multiple API in a single tablet, with different release profiles.  In addition to shown improvement in mass variability between layers, OptiDose also offers tablet design to minimize cross-layer interaction of API and improved product stability.

One of the more recognized approaches for developing high quality controlled release formulations, Wurster fluid bed technology is a bottom-spray approach, where a coating medium is sprayed onto the particle. Compared to alternative technologies, it produces a more consistent coating for powders, granules, pellets, and micro-tablets, with higher quality controlled release product due to more predictable residence time within the coating zone.

Catalent recently invested in major capacity expansions at its Schorndorf, Germany; Somerset, NJ; and Winchester, KY, facilities to increase fluid bed capacity and capabilities to meet growing customer demand.

Company name:  Catalent Pharma Solutions
Website: www.catalent.com
E-mail: info@catalent.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here